B cells in the mature tertiary lymphoid structures (TLS) could not only secrete antibodies but also mediate tumor apoptosis, phagocytosis, and antibody-dependent cellular cytotoxicity (as shown in Fig.1), which results in improving patient overall survival. To help overcome the obstacles of taking B-cell immunotherapy into practice, we provide the in vivo survival assessment service to fulfill the related critical needs.